(lp0
S'Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros MD ... PR Newswire  - Jan 6, 2017 SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. , a biotechnology company focused on neurological and endocrine related disorders, announced that David-Alexandre &quot;DA&quot; Gros M.D.What Does The Panel Cancellation Mean For Neurocrine Biosciences, Inc. (NASDAQ ... - Market Exclusive'
p1
aS'Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for ... PR Newswire  - Feb 9, 2017 SAN DIEGO and PORTO, Portugal, Feb. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc.  and BIAL today announced that they have entered into an exclusive licensing agreement for the development and commercialization of&nbsp;...Neurocrine Bio nabs North American rights to PD med opicapone - Seeking AlphaNeurocrine Biosciences : Physician Survey Shows Strong Demand For VMAT2 ... - StreetInsider.com'
p2
aS'Neurocrine Biosciences Building Toward Bigger Things Seeking Alpha - Feb 16, 2017 Neurocrine is heading toward multiple major milestones in 2017, including potential approval of its first drug, an NDA filling for another, and an important gating Phase II study.'
p3
aS'The Positive Investment Case For Neurocrine Biosciences Seeking Alpha - Feb 3, 2017 Founded in 1996, Neurocrine Biosciences is a San Diego, CA,-based biopharmaceutical concern with two late-stage clinical programs that are focused on neurological and endocrine based diseases and disorders.'
p4
aS'Has Neurocrine Biosciences Hit A Jackpot With Ingrezza? Seeking Alpha - Dec 5, 2016 Today, Neurocrine Biosciences  is at the cusp of a major transformation, from being an R&amp;D focused company to a commercial organization.'
p5
aS"Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA ... PR Newswire  - Aug 31, 2016 SAN DIEGO, Aug. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc.  today announced that the U.S. Food and Drug Administration  has conditionally accepted the proprietary name &quot;INGREZZA&quot; for the Company's once-daily&nbsp;...Neurocrine Biosciences  Submitted The Valbenazine NDA Earlier Than ... - StreetInsider.com"
p6
aS"Neurocrine Announces INGREZZA  New Drug Application for the ... PR Newswire  - Oct 11, 2016 SAN DIEGO, Oct. 11, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc.  today announced that the U.S. Food and Drug Administration  has accepted for Priority Review the New Drug Application  for INGREZZATM &nbsp;...Neurocrine's Ingrezza NDA for involuntary movement disorder accepted under ... - Seeking Alpha"
p7
aS"Busy Neurocrine Biosciences Faces A Phase II Setback Seeking Alpha - Jan 18, 2017 Neurocrine Biosciences disappointed an already skittish and sour biotech investor community with disappointing results from a Phase II study of valbenazine in adult Tourette's.Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor ... - PR Newswire Analysts Outlook and Insider Trading Summary: Neurocrine Biosciences, Inc ... - Post Registrar"
p8
aS"Institutions Attracted to This Stock; Holding Majority of Shares: Neurocrine ... Midway Monitor - 8 hours ago Neurocrine Biosciences, Inc. 's stock has been a favorite of smart money aka institutions, as of late.Share Watch: Examining the Levels for Neurocrine Biosciences, Inc.  - The StandardNeurocrine Biosciences, Inc.  Stock Rating Reaffirmed by Cantor Fitzgerald - Sports Perspectives"
p9
aS'Neurocrine Biosciences Stock Could See A Run-Up Seeking Alpha - Nov 9, 2016 Neurocrine Biosciences has several upcoming catalysts, including PDUFA for Valbenazine  in April, 2017 and planned NDA for elagolix in endometriosis  in 2017.'
p10
a.